|
EPB41L1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.49489999992747E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.65400000052519E-07 |
| Normal-vs-Stage2 |
7.342800E-03 |
| Normal-vs-Stage3 |
6.20639999999728E-05 |
| Normal-vs-Stage4 |
5.62840000000175E-05 |
| Stage1-vs-Stage2 |
9.057400E-01 |
| Stage1-vs-Stage3 |
8.001600E-01 |
| Stage1-vs-Stage4 |
7.456800E-01 |
| Stage2-vs-Stage3 |
9.606200E-01 |
| Stage2-vs-Stage4 |
7.677400E-01 |
| Stage3-vs-Stage4 |
6.392600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.00429999982943E-07 |
| Normal-vs-AfricanAmerican |
3.679700E-03 |
| Normal-vs-Asian |
1.157550E-04 |
| Caucasian-vs-AfricanAmerican |
8.269400E-01 |
| Caucasian-vs-Asian |
9.686200E-01 |
| AfricanAmerican-vs-Asian |
8.058600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.34410000005325E-06 |
| Normal-vs-Female |
6.67460000047804E-07 |
| Male-vs-Female |
7.419800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.8105000005052E-07 |
| Normal-vs-Age(41-60Yrs) |
1.53550000003833E-06 |
| Normal-vs-Age(61-80Yrs) |
7.216900E-04 |
| Normal-vs-Age(81-100Yrs) |
4.740600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.553200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.711590E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.884440E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.661600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.111400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.752000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.992400E-01 |
| Classical-VS-Follicular |
8.58840000228511E-08 |
| Classical-VS-Other |
8.529200E-01 |
| Classical-VS-Normal |
1.86519999445522E-09 |
| Tall-VS-Follicular |
1.801000E-04 |
| Tall-VS-Other |
6.549200E-01 |
| Tall-VS-Normal |
2.09709999998697E-06 |
| Follicular-VS-Other |
1.211550E-01 |
| Follicular-VS-Normal |
4.753800E-01 |
| Other-VS-Normal |
1.891410E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.167600E-04 |
| Normal-vs-N1 |
5.340700E-03 |
| N0-vs-N1 |
8.741800E-01 |
|
|
